🎁 A holiday package to celebrate the season! Click here and shop now!

TextRanch

The best way to perfect your writing.

Discover why 1,062,726 users count on TextRanch to get their English corrected!

1. Input your text below.
2. Get it corrected in a few minutes by our editors.
3. Improve your English!

One of our experts will correct your English.

Our experts

are at increased risk of contracting vs are at an increased risk of contracting

Both phrases are correct, but they are used in slightly different contexts. The phrase 'are at increased risk of contracting' is more concise and direct, while 'are at an increased risk of contracting' is more formal and emphasizes the specific increase in risk. The choice between them depends on the desired tone and emphasis in the sentence.

Last updated: March 22, 2024 • 536 views

are at increased risk of contracting

This phrase is correct and commonly used in English.

This phrase is a concise way to indicate that someone is at a higher risk of contracting something.
  • Children under five who live near nuclear power stations run an increased risk of contracting cancer.
  • Patients receiving zidovudine in combination with ribavirin and alpha interferons are at increased risk of developing anaemia.
  • Patients with underlying neuromuscular disorders including swallowing disorders are at increased risk of these undesirable effects.
  • Patients with underlying neurological disorders including swallowing difficulties are at increased risk of these side effects.
  • Neoplasms benign, malignant and unspecified Patients receiving immunosuppressive therapy are at increased risk of developing malignancies.
  • Neoplasms benign, malignant and unspecified (incl cysts and polyps) Patients receiving immunosuppressive therapy are at increased risk of developing malignancies.
  • Patients receiving immunosuppressive regimens involving combinations of medicinal products, including CellCept, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.8).
  • Patients receiving immunosuppressive regimens involving combinations of medicinal products, including Myfenax, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.8).
  • During the construction work several workers using Rhoca-Gil sealing compound suffered damage to the nervous system and are at increased risk of cancer.
  • Haemorrhagic risk Several sub-groups of patients, as detailed below, are at increased risk of bleeding.
  • Patients taking concomitant oral corticosteroids, selective serotonin reuptake inhibitors (SSRIs) or anti-platelet agents such as low-dose acetylsalicylic acid are at increased risk of serious GI complications (see below and section 4.5).
  • Patients with chronic hepatitis B or C and treated with antiretroviral agents are at increased risk of severe and potentially fatal liver adverse events and may require blood tests for monitoring of liver function.
  • Patients receiving immunosuppressive regimens involving combinations of medicinal products, including CellCept, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.4).
  • All transplant patients are at increased risk of opportunistic infections; the risk increased with total immunosuppressive load (see section 4.4).
  • Prophylaxis of VTE - Patients with creatinine clearance < 50 ml/ min are at increased risk of bleeding and VTE and should be treated with caution (see sections 4.2, 4.3 and 5.2).
  • Patients receiving immunosuppressive regimens involving combinations of medicinal products, including Mycophenolate mofetil Teva, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.8).
  • Patients with chronic hepatitis B or C infection treated with combination antiretroviral therapy are at increased risk of experiencing severe, and potentially fatal, hepatic adverse events.
  • Patients with chronic hepatitis B or C and treated with antiretroviral agents are at increased risk of severe and potentially fatal liver adverse events and may require blood tests for monitoring of liver function.
  • Patients with creatinine clearance < 50 ml/ min are at increased risk of bleeding and VTE and should be treated with caution (see sections 4.2, 4.3 and 5.2).
  • The following patients are at increased risk for developing liver problems:

Alternatives:

  • are at a higher risk of contracting
  • are at an elevated risk of contracting
  • are at greater risk of contracting
  • are at an increased risk for contracting
  • are at risk of contracting

are at an increased risk of contracting

This phrase is correct and commonly used in English.

This phrase is more formal and emphasizes the specific increase in risk that someone is facing.
  • Your doctor has prescribed this medicine for you because after an operation you are at an increased risk of getting blood clots.
  • Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk of severe and potentially fatal hepatic adverse events.
  • IDflu is used to vaccinate adults against flu, especially those who are at an increased risk of developing complications of the disease.
  • Patients with chronic hepatitis B or C treated with antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions.
  • Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse events.
  • Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse events.
  • Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse events.
  • Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse events.
  • Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions.
  • Patients with chronic hepatitis B or C and treated with combination anti-retroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse events.
  • Patients with chronic hepatitis B and C and treated with antiretroviral therapy are at an increased risk for serious liver problems.
  • Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse events.
  • Children under five who live near nuclear power stations run an increased risk of contracting cancer.
  • If you are at an increased risk of heart disease, {PRODUCT NAME} can also be used to reduce such risk even if your cholesterol levels are normal.
  • Patients undergoing ovarian stimulation are at an increased risk of developing ovarian hyperstimulation syndrome (OHSS) due to multiple follicular development
  • Patients undergoing stimulation of follicular growth are at an increased risk of developing hyperstimulation in view of possible excessive oestrogen response and multiple follicular development.
  • Patients receiving other medicinal products inhibiting the renin-angiotensin system (RAS), and/ or those with reduced kidney function and/ or diabetes mellitus are at an increased risk of hyperkalaemia during aliskiren therapy.
  • Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions.
  • Patients who receive cetuximab in combination with platinum-based chemotherapy are at an increased risk for the occurrence of severe neutropenia, which may lead to subsequent infectious complications such as febrile neutropenia, pneumonia or sepsis.
  • Oxyglobin should not be used in animals that have received Oxyglobin in the past, or in dogs that are at an increased risk of circulatory overload with conditions such as oliguria or anuria (infrequent or no urination) or advanced heart disease.

Alternatives:

  • are at a heightened risk of contracting
  • are at a raised risk of contracting
  • are at an escalated risk of contracting
  • are at an increased risk for contracting
  • are at risk of contracting

Related Comparisons

H is committed to reducing the occurrence of injuries at workplaces. vs H is committed to reduce the occurrence of injuries at workplaces. households threatened by fuel poverty vs households at risk of fuel poverty is afraid to fall vs is afraid of falling poverty risk vs risk of poverty reduction in number of variables vs reduction the in number of variables prospect of change was growing rapidly vs was growing

What Our Customers Are Saying

Our customers love us! We have an average rating of 4.79 stars based on 283,125 votes.
Also check out our 2,100+ reviews on TrustPilot (4.9TextRanch on TrustPilot).

Why choose TextRanch?

Lowest prices
Up to 50% lower than other online editing sites.

Fastest Times
Our team of editors is working for you 24/7.

Qualified Editors
Native English experts for UK or US English.

Top Customer Service
We are here to help. Satisfaction guaranteed!

×

💝 TextRanch Holidays Offer! 💝️

25% special discount
Stock up on credits for the entire year!

Grab this offer now!